Avacincaptad pegol sodium
Highest phase reached
Approved
Drug type
Oligonucleotide
First approval year
2023
- First approval year
- 2023
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Oligonucleotide
- Drug name
- Avacincaptad pegol sodium
- izervay
- Izervay
- arc 1905
- ARC-1905
- arc1905
- Arc1905
- ARC1905
- avacincaptad pegol sodium
- Avacincaptad pegol sodium
- Avacincaptad pegol sodium [MI]
- AVACINCAPTAD PEGOL SODIUM [USAN]
- Avacincaptad pegol sodium [WHO-DD]
- avacincaptad pegol sodium mi
- avacincaptad pegol sodium usan
- avacincaptad pegol sodium who dd
- izervay
- Izervay™
- CAS registry numbers
- 1491144-00-3
- ChEMBL ID
- CHEMBL4297889
- RxNorm IDs (RxCUI)
- 2645107
- FDA ingredient codes (UNII)
- K86ENL12I5
- Applicant
- ASTELLAS
- Approval date
- 4 Aug 2023
- Application number
- NDA217225
- Patents
- 6
- Designations
- 0
- Earliest recorded loss of exclusivity
- 11 Jul 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- avacincaptad pegol
- Type
- Nucleic acid
- Drug name stem
- peg-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Binding
- Action type
- Binding
- Target
- complement C5
- Gene symbol
- complement C5
- Median affinity
- 9.82
- Affinity units
- pIC50
- Mechanism
- Complement C5 inhibitor
- Action type
- Inhibitor
- Target
- Complement C5
- Protein identifier
- P01031
Open Targets mechanisms
- Mechanism
- Complement C5 inhibitor
- Action type
- Inhibitor
- Target
- Complement C5
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009606
- Subject identifier
- D008268
- Condition
- Geographic Atrophy
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001492
- Subject identifier
- D057092
- Condition identifier
- EFO_0001365
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009606
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001492
- Condition identifier
- EFO_1001492
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003004
- Highest recorded phase
- 1
- Event
- intercepted product preparation error
- Reports
- 15
- Reporting signal score
- 70.2914
- Event
- needle issue
- Reports
- 18
- Reporting signal score
- 76.2788
- NCT00709527
- NCT00950638
- NCT03362190
- NCT02686658
- NCT05571267
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- 82829-002
Related records
Trials (2)
- A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
In development for (2)
- Age-related macular degeneration Phase 2
- Macular degeneration Phase 2
Targets (1)
- C5 Complement C5 inhibitor